Literature DB >> 15282324

Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter.

Luigi Cicatiello1, Raffaele Addeo, Annarita Sasso, Lucia Altucci, Valeria Belsito Petrizzi, Raphaelle Borgo, Massimo Cancemi, Simona Caporali, Silvana Caristi, Claudio Scafoglio, Diana Teti, Francesco Bresciani, Bruno Perillo, Alessandro Weisz.   

Abstract

Transcriptional activation of the cyclin D1 gene (CCND1) plays a pivotal role in G(1)-phase progression, which is thereby controlled by multiple regulatory factors, including nuclear receptors (NRs). Appropriate CCND1 gene activity is essential for normal development and physiology of the mammary gland, where it is regulated by ovarian steroids through a mechanism(s) that is not fully elucidated. We report here that CCND1 promoter activation by estrogens in human breast cancer cells is mediated by recruitment of a c-Jun/c-Fos/estrogen receptor alpha complex to the tetradecanoyl phorbol acetate-responsive element of the gene, together with Oct-1 to a site immediately adjacent. This process coincides with the release from the same DNA region of a transcriptional repressor complex including Yin-Yang 1 (YY1) and histone deacetylase 1 and is sufficient to induce the assembly of the basal transcription machinery on the promoter and to lead to initial cyclin D1 accumulation in the cell. Later on in estrogen stimulation, the cyclin D1/Cdk4 holoenzyme associates with the CCND1 promoter, where E2F and pRb can also be found, contributing to the long-lasting gene enhancement required to drive G(1)-phase completion. Interestingly, progesterone triggers similar regulatory events through its own NRs, suggesting that the gene regulation cascade described here represents a crossroad for the transcriptional control of G(1)-phase progression by different classes of NRs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15282324      PMCID: PMC479712          DOI: 10.1128/MCB.24.16.7260-7274.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  69 in total

1.  A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome.

Authors:  Luigi Cicatiello; Claudio Scafoglio; Lucia Altucci; Massimo Cancemi; Guido Natoli; Angelo Facchiano; Giovanni Iazzetti; Raffaele Calogero; Nicoletta Biglia; Michele De Bortoli; Christian Sfiligoi; Piero Sismondi; Francesco Bresciani; Alessandro Weisz
Journal:  J Mol Endocrinol       Date:  2004-06       Impact factor: 5.098

2.  CDK-independent activation of estrogen receptor by cyclin D1.

Authors:  R M Zwijsen; E Wientjens; R Klompmaker; J van der Sman; R Bernards; R J Michalides
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

3.  Differential expression of the human ST5 gene in HeLa-fibroblast hybrid cell lines mediated by YY1: evidence that YY1 plays a part in tumor suppression.

Authors:  J H Lichy; M Majidi; J Elbaum; M M Tsai
Journal:  Nucleic Acids Res       Date:  1996-12-01       Impact factor: 16.971

4.  A new method for sequencing DNA.

Authors:  A M Maxam; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

5.  Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint.

Authors:  J Lukas; J Bartkova; J Bartek
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

Review 6.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

7.  A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer.

Authors:  Justin Lamb; Sridhar Ramaswamy; Heide L Ford; Bernardo Contreras; Robert V Martinez; Frances S Kittrell; Cynthia A Zahnow; Nick Patterson; Todd R Golub; Mark E Ewen
Journal:  Cell       Date:  2003-08-08       Impact factor: 41.582

8.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

9.  Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter.

Authors:  Raphaël Métivier; Graziella Penot; Michael R Hübner; George Reid; Heike Brand; Martin Kos; Frank Gannon
Journal:  Cell       Date:  2003-12-12       Impact factor: 41.582

10.  Isolation and characterization of the human nucleophosmin/B23 (NPM) gene: identification of the YY1 binding site at the 5' enhancer region.

Authors:  P K Chan; F Y Chan; S W Morris; Z Xie
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

View more
  70 in total

1.  ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells.

Authors:  Christy R Hagan; Tarah M Regan; Gwen E Dressing; Carol A Lange
Journal:  Mol Cell Biol       Date:  2011-04-25       Impact factor: 4.272

Review 2.  Progesterone receptors, their isoforms and progesterone regulated transcription.

Authors:  Britta M Jacobsen; Kathryn B Horwitz
Journal:  Mol Cell Endocrinol       Date:  2011-09-17       Impact factor: 4.102

3.  Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor.

Authors:  Chunyu Wang; Julie Ann Mayer; Abhijit Mazumdar; Kirsten Fertuck; Heetae Kim; Myles Brown; Powel H Brown
Journal:  Mol Endocrinol       Date:  2011-08-11

4.  Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3.

Authors:  Wendy Béguelin; María Celeste Díaz Flaqué; Cecilia J Proietti; Florencia Cayrol; Martín A Rivas; Mercedes Tkach; Cinthia Rosemblit; Johanna M Tocci; Eduardo H Charreau; Roxana Schillaci; Patricia V Elizalde
Journal:  Mol Cell Biol       Date:  2010-09-27       Impact factor: 4.272

Review 5.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

6.  Research resource: progesterone receptor targetome underlying mammary gland branching morphogenesis.

Authors:  Ashlee R Lain; Chad J Creighton; Orla M Conneely
Journal:  Mol Endocrinol       Date:  2013-08-26

7.  Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos.

Authors:  Jennifer H Gutzman; Sarah E Nikolai; Debra E Rugowski; Jyoti J Watters; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2005-03-03

8.  Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor β via microRNAs.

Authors:  Giovanni Nassa; Roberta Tarallo; Giorgio Giurato; Maria Rosaria De Filippo; Maria Ravo; Francesca Rizzo; Claudia Stellato; Concetta Ambrosino; Marc Baumann; Niina Lietzèn; Tuula A Nyman; Alessandro Weisz
Journal:  Mol Cell Proteomics       Date:  2014-02-13       Impact factor: 5.911

9.  Mutational analysis of progesterone receptor functional domains in stable cell lines delineates sets of genes regulated by different mechanisms.

Authors:  Ignacio Quiles; Lluís Millán-Ariño; Alicia Subtil-Rodríguez; Belén Miñana; Nora Spinedi; Cecilia Ballaré; Miguel Beato; Albert Jordan
Journal:  Mol Endocrinol       Date:  2009-03-19

10.  Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors.

Authors:  Emily J Faivre; Andrea R Daniel; Christopher J Hillard; Carol A Lange
Journal:  Mol Endocrinol       Date:  2008-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.